Preclinical studies of toxic and pharmacologic properties of temozolomide immobilized on highly substituted dextrane phosphate for local chemotherapy of central nervous system tumors Part I. Acute toxicity
Results of acute toxicity experiments of finished dosage form for local chemotherapy of malignant brain tumors are presented for antitumor drug substance temozolomide immobilized on highly substituted dextrane phosphate. Basing on gained data average lethal dose (LD50) is calculated as well as death threshold dose (LD10), a dose causing death of most experimental animals (LD90), and minimal absolutely lethal dose (LD99). It was shown that by value of average lethal dose (LD50) this medication belongs to IV toxicityclass and is «almost harmless».